Christopher Liu
Stock Analyst at Lucid Capital
(3.80)
# 1,975
Out of 5,058 analysts
150
Total ratings
42.3%
Success rate
8.5%
Average return
Main Sectors:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVCT Nuvectis Pharma | Reiterated: Buy | $22 → $34 | $18.93 | +79.61% | 3 | Aug 5, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Buy | $14 → $4 | $0.971 | +311.95% | 2 | Jun 5, 2026 | |
| NXTC NextCure | Reiterated: Buy | $25 | $6.88 | +263.37% | 2 | Jun 2, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $50 | $20.60 | +142.72% | 1 | May 28, 2026 | |
| ACTU Actuate Therapeutics | Reiterated: Buy | $5 | $0.4999 | +900.20% | 1 | May 18, 2026 | |
| RLMD Relmada Therapeutics | Initiated Coverage: Buy | $14 | $3.20 | +337.50% | 1 | Mar 2, 2026 | |
| TVRD Tvardi Therapeutics | Upgraded: Buy | $42 → $6 | $1.07 | +460.75% | 2 | Feb 4, 2026 | |
| ANL Adlai Nortye Group | Initiated Coverage: Buy | $11 | $12.09 | -9.02% | 1 | Jan 29, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $50 | $14.69 | +240.37% | 1 | Dec 15, 2025 | |
| IPHA Innate Pharma | Initiated Coverage: Buy | $8 | $1.48 | +440.54% | 1 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $8.19 | n/a | 1 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $2.40 | n/a | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $2.48 | n/a | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $1.29 | n/a | 1 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $19 → $37 | $62.83 | n/a | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 → $36 | $24.95 | n/a | 20 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $2.34 | n/a | 1 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $33.85 | n/a | 7 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $29.51 | n/a | 28 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $17.30 | n/a | 4 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $2.78 | n/a | 14 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $77 | $7.16 | n/a | 22 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $10.12 | n/a | 12 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $13 | $10.27 | n/a | 2 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $27 | $4.24 | n/a | 2 | Aug 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.3765 | n/a | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $36.33 | n/a | 2 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $16.48 | n/a | 2 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.635 | n/a | 1 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.066 | n/a | 2 | Jul 6, 2018 |
Nuvectis Pharma
Aug 5, 2026
Reiterated: Buy
Price Target: $22 → $34
Current: $18.93
Upside: +79.61%
Cardiff Oncology
Jun 5, 2026
Reiterated: Buy
Price Target: $14 → $4
Current: $0.971
Upside: +311.95%
NextCure
Jun 2, 2026
Reiterated: Buy
Price Target: $25
Current: $6.88
Upside: +263.37%
Faeth Therapeutics
May 28, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $20.60
Upside: +142.72%
Actuate Therapeutics
May 18, 2026
Reiterated: Buy
Price Target: $5
Current: $0.4999
Upside: +900.20%
Relmada Therapeutics
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $3.20
Upside: +337.50%
Tvardi Therapeutics
Feb 4, 2026
Upgraded: Buy
Price Target: $42 → $6
Current: $1.07
Upside: +460.75%
Adlai Nortye Group
Jan 29, 2026
Initiated Coverage: Buy
Price Target: $11
Current: $12.09
Upside: -9.02%
Ascentage Pharma Group International
Dec 15, 2025
Initiated Coverage: Buy
Price Target: $50
Current: $14.69
Upside: +240.37%
Innate Pharma
Oct 23, 2025
Initiated Coverage: Buy
Price Target: $8
Current: $1.48
Upside: +440.54%
Sep 26, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $8.19
Upside: n/a
Sep 18, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $2.40
Upside: n/a
Jul 21, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $2.48
Upside: n/a
May 28, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $1.29
Upside: n/a
May 14, 2025
Reiterated: Hold
Price Target: $19 → $37
Current: $62.83
Upside: n/a
Apr 9, 2025
Reiterated: Buy
Price Target: $28 → $36
Current: $24.95
Upside: n/a
Jan 27, 2025
Reiterated: Buy
Price Target: $20
Current: $2.34
Upside: n/a
Feb 21, 2024
Reiterated: Buy
Price Target: $50
Current: $33.85
Upside: n/a
Feb 20, 2024
Reiterated: Buy
Price Target: n/a
Current: $29.51
Upside: n/a
Feb 13, 2024
Reiterated: Buy
Price Target: $18
Current: $17.30
Upside: n/a
Dec 13, 2023
Reiterated: Buy
Price Target: $14
Current: $2.78
Upside: n/a
Dec 8, 2023
Reiterated: Buy
Price Target: $70 → $77
Current: $7.16
Upside: n/a
Nov 9, 2023
Reiterated: Hold
Price Target: $5
Current: $10.12
Upside: n/a
Aug 9, 2018
Rated: Buy
Price Target: $13
Current: $10.27
Upside: n/a
Aug 2, 2018
Rated: Buy
Price Target: $27
Current: $4.24
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $0.3765
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $36.33
Upside: n/a
Jul 6, 2018
Reiterated: Hold
Price Target: n/a
Current: $16.48
Upside: n/a
Jul 6, 2018
Reiterated: Hold
Price Target: n/a
Current: $0.635
Upside: n/a
Jul 6, 2018
Reiterated: Hold
Price Target: n/a
Current: $0.066
Upside: n/a